高级检索

    血清胃蛋白酶原对胃癌患者预后的预测价值

    The predicting value of serum pepsinogen in the prognosis of patients with gastric cancer

    • 摘要: 目的 探讨血清胃蛋白酶原对胃癌患者预后的预测价值。方法 回顾性收集汉中市人民医院及汉中市中心医院2015年1月—2016年9月收治的118例胃癌患者的临床资料,分析患者入院时血清胃蛋白酶原、糖类抗原199(CA199)、癌胚抗原(CEA)水平,行胃癌根治术和化疗后随访2年,观察血清胃蛋白酶原、CA199、CEA对胃癌患者2年内死亡的预测价值。结果 与存活患者比较,死亡患者CA199显著升高〔(48.43±17.04) U/ml vs. (36.71±15.78) U/ml, P=0.000〕、CEA显著升高〔(53.97±22.12) μg/L vs. (41.62±11.54)μg/L, P=0.000〕、胃蛋白酶原Ⅰ显著降低〔(30.55±5.74)μg/L vs. (44.00±8.44) μg/L, P=0.000〕、胃蛋白酶原Ⅱ显著增高〔(19.09±5.81)μg/L vs. (16.16±5.11) μg/L, P=0.005〕。胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ、CA199、CEA对预测胃癌患者2年内死亡具有一定价值,其中胃蛋白酶原Ⅰ价值最高〔95% CI, 0.094(0.042~0.147), P=0.000〕。结论 胃蛋白酶原Ⅰ对胃癌患者预后的预测价值较高,值得推广。

       

      Abstract: Objective To explore the predictive value of serum pepsinogen in the prognosis of patients with gastric cancer. Methods A total of 118 patients with gastric cancer admitted to the People's Hospital of Hanzhong and Hanzhong Central Hospital from January 2015 to September 2016 were retrospectively collected. The serum levels of pepsinogen, carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) were measured on admission. After radical gastrectomy and chemotherapy, the patients were followed up for 2 years. The predictive value of serum pepsinogen, CA199 and CEA on the death of gastric cancer patients within 5 years were observed. Results When compared with the survivors, CA199 was significantly increased in patients who died (48.43±17.04) U/ml vs. (36.71±15.78) U/ml, P=0.000; CEA was significantly increased (53.97±22.12) μg/L vs. (41.62±11.54) μg/L, P=0.000; pepsinogen I was significantly decreased (30.55±5.74) μg/L vs. (44.00±8.44) μg/L, P=0.000; and pepsinogen Ⅱ was significantly increased (19.09±5.81)μg/L vs. (16.16±5.11) μg/L, P=0.005. PepsinogenⅠ, pepsinogen Ⅱ, CA199 and CEA had some values in predicting the death of gastric cancer patients within 2 years, but pepsinogen Ⅰ had the highest value 95% CI, 0.094 (0.042-0.147), P=0.000. Conclusions The pepsinogenⅠ has a higher predictive value for the prognosis of patients with gastric cancer, and is worthy of promotion.

       

    /

    返回文章
    返回